{"nersets":[[{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"32","endOffset":"44","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","prefix":"Following coadministration with ","suffix":", rosuvastatin geometric least square mean AUC(0,","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"","suffix":" did not produce any change in rosuvastatin pharmacokinetics","exact":"Ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"8","endOffset":"20","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","prefix":"CYP3A4, ","suffix":", P-glycoprotein, rosuvastatin","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"","suffix":" is also known to inhibit the activity of transport protein ","exact":"Ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"213","endOffset":"225","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":". Volunteers were randomized to receive daily oral doses of ","suffix":" 400 mg (1 × 200-mg tablet every 12 h) or matching placebo (","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"525","endOffset":"537","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"mg (1 × 80-mg encapsulated tablet) with the morning dose of ","suffix":" or placebo. Volunteers then remained in the Clinical Pharma","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"278","endOffset":"290","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"mples were taken before administration of the first dose of ","suffix":" or placebo on day 1 of the second dosing period. Blood samp","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"en before and 2 h after administration of the first dose of ","suffix":" or placebo on days 4, 5, 6 and 7 of each dosing period. Blo","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"18","endOffset":"30","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"Lack of effect of ","suffix":" on the pharmacokinetics of rosuvastatin in healthy subjects","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"32","endOffset":"44","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","prefix":"Following coadministration with ","suffix":", rosuvastatin geometric least square mean AUC(0,","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"8","endOffset":"20","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","prefix":"CYP3A4, ","suffix":", P-glycoprotein, rosuvastatin","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"213","endOffset":"225","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":". Volunteers were randomized to receive daily oral doses of ","suffix":" 400 mg (1 × 200-mg tablet every 12 h) or matching placebo (","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"525","endOffset":"537","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"mg (1 × 80-mg encapsulated tablet) with the morning dose of ","suffix":" or placebo. Volunteers then remained in the Clinical Pharma","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"278","endOffset":"290","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"mples were taken before administration of the first dose of ","suffix":" or placebo on day 1 of the second dosing period. Blood samp","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"en before and 2 h after administration of the first dose of ","suffix":" or placebo on days 4, 5, 6 and 7 of each dosing period. Blo","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"122","endOffset":"134","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"dence interval (CI) for the treatment ratio (rosuvastatin + ","suffix":"/rosuvastatin + placebo) of the geometric least square means","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"88","endOffset":"100","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"trations of rosuvastatin over time when coadministered with ","suffix":" or placebo. ○, Rosuvastatin + ketoconazole; ▪, rosuvastatin","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"131","endOffset":"143","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"dministered with ketoconazole or placebo. ○, Rosuvastatin + ","suffix":"; ▪, rosuvastatin + placebo.","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"155","endOffset":"167","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"astatin over time when rosuvastatin was coadministered with ","suffix":". A similar pattern was seen when rosuvastatin was coadminis","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"17","endOffset":"29","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"Rosuvastatin and ","suffix":" were well tolerated when coadministered. There were no seri","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"65","endOffset":"77","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"inistration of rosuvastatin and the potent CYP3A4 inhibitor ","suffix":" did not produce any change in pharmacokinetics of the forme","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"178","endOffset":"190","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"netics of the former. Furthermore, the results suggest that ","suffix":" had no effect on the systemic clearance of rosuvastatin, as","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"In conclusion, ","suffix":" did not affect the pharmacokinetics of rosuvastatin in heal","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"132","endOffset":"144","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"astatin in healthy subjects. Therefore, coadministration of ","suffix":" and rosuvastatin is unlikely to increase the risk of toxici","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"303","endOffset":"315","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[1]/p[1]","prefix":"Sciences Inc. (Montreal, Quebec, Canada) for performing the ","suffix":" assays, Olise M. Nwose MB BS for his support of this trial,","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"88","endOffset":"100","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"trations of rosuvastatin over time when coadministered with ","suffix":" or placebo. ○, Rosuvastatin + ketoconazole; ▪, rosuvastatin","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"88","endOffset":"100","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"trations of rosuvastatin over time when coadministered with ","suffix":" or placebo. ○, Rosuvastatin + ketoconazole; ▪, rosuvastatin","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"131","endOffset":"143","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"dministered with ketoconazole or placebo. ○, Rosuvastatin + ","suffix":"; ▪, rosuvastatin + placebo.","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"155","endOffset":"167","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"astatin over time when rosuvastatin was coadministered with ","suffix":". A similar pattern was seen when rosuvastatin was coadminis","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"17","endOffset":"29","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"Rosuvastatin and ","suffix":" were well tolerated when coadministered. There were no seri","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"65","endOffset":"77","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"inistration of rosuvastatin and the potent CYP3A4 inhibitor ","suffix":" did not produce any change in pharmacokinetics of the forme","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"178","endOffset":"190","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"netics of the former. Furthermore, the results suggest that ","suffix":" had no effect on the systemic clearance of rosuvastatin, as","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"151","endOffset":"163","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ion for, or induction or inhibition of, transport proteins. ","suffix":" is known to have inhibitory effects on the transport protei","exact":"Ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"In conclusion, ","suffix":" did not affect the pharmacokinetics of rosuvastatin in heal","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"132","endOffset":"144","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"astatin in healthy subjects. Therefore, coadministration of ","suffix":" and rosuvastatin is unlikely to increase the risk of toxici","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"303","endOffset":"315","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[1]/p[1]","prefix":"Sciences Inc. (Montreal, Quebec, Canada) for performing the ","suffix":" assays, Olise M. Nwose MB BS for his support of this trial,","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","prefix":"Following coadministration with ketoconazole, ","suffix":" geometric least square mean AUC(0,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"43","endOffset":"55","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"Ketoconazole did not produce any change in ","suffix":" pharmacokinetics in healthy subjects. The data suggest that","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"206","endOffset":"218","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"357","endOffset":"369","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","prefix":"CYP3A4, ketoconazole, P-glycoprotein, ","suffix":"","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"","suffix":" (Crestor®) is an inhibitor of 3-hydroxy-3-methylglutaryl co","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"","suffix":" and ketoconazole were well tolerated when coadministered. T","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"crestor","startOffset":"14","endOffset":"21","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"Rosuvastatin (","suffix":"®) is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A ","exact":"Crestor"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"243","endOffset":"255","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"The pharmacokinetics of ","suffix":" following single- and multiple-dose administration of the d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"Elimination of ","suffix":" is primarily via the liver. In a clinical trial [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"Lack of effect of ketoconazole on the pharmacokinetics of ","suffix":" in healthy subjects","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","prefix":"Following coadministration with ketoconazole, ","suffix":" geometric least square mean AUC(0,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"43","endOffset":"55","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"Ketoconazole did not produce any change in ","suffix":" pharmacokinetics in healthy subjects. The data suggest that","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","prefix":"CYP3A4, ketoconazole, P-glycoprotein, ","suffix":"","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"243","endOffset":"255","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"The pharmacokinetics of ","suffix":" following single- and multiple-dose administration of the d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"Elimination of ","suffix":" is primarily via the liver. In a clinical trial [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"337","endOffset":"349","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[1]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[1]/p[2]","prefix":"uring the washout period following the first dosing period (","suffix":" + placebo)]. This withdrawal was considered unlikely to hav","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"449","endOffset":"461","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"194","endOffset":"206","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":" the first dose on day 1 until 96 h after administration of ","suffix":" in each dosing period), the consumption of caffeine-contain","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"372","endOffset":"384","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"om midnight before day 1 until 96 h after administration of ","suffix":" in each dosing period), and concomitant medications (none p","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"25","endOffset":"37","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"Blood samples (9 ml) for ","suffix":" assay were taken before administration of rosuvastatin on d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" for rosuvastatin assay were taken before administration of ","suffix":" on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"28","endOffset":"40","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"The blood samples taken for ","suffix":" assay were also used to obtain plasma for active and total ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"107","endOffset":"119","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"t the 90% confidence interval (CI) for the treatment ratio (","suffix":" + ketoconazole/rosuvastatin + placebo) of the geometric lea","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"135","endOffset":"147","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"l (CI) for the treatment ratio (rosuvastatin + ketoconazole/","suffix":" + placebo) of the geometric least square means (gls","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"40","endOffset":"52","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"Geometric mean plasma concentrations of ","suffix":" over time when coadministered with ketoconazole or placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"148","endOffset":"160","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"ketoconazole or placebo. ○, Rosuvastatin + ketoconazole; ▪, ","suffix":" + placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"Summary pharmacokinetic parameters of ","suffix":", and results of the statistical analysis of the plasma AUC(","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"94","endOffset":"106","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ma concentration-time curves measured to a common point for ","suffix":" and active and total HMG-CoA reductase inhibitors indicated","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"230","endOffset":"242","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"ations of active and total HMG-CoA reductase inhibitors and ","suffix":" over time when rosuvastatin was coadministered with ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"MG-CoA reductase inhibitors and rosuvastatin over time when ","suffix":" was coadministered with ketoconazole. A similar pattern was","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"201","endOffset":"213","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"nistered with ketoconazole. A similar pattern was seen when ","suffix":" was coadministered with placebo. ○,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"20","endOffset":"32","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"Coadministration of ","suffix":" and the potent CYP3A4 inhibitor ketoconazole did not produc","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"234","endOffset":"246","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"hat ketoconazole had no effect on the systemic clearance of ","suffix":", as individual plasma concentration profiles, including the","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"In contrast to ","suffix":", atorvastatin [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"oncentrations were measured in this trial. The finding that ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"327","endOffset":"339","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"643","endOffset":"655","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" support for previous data indicating limited metabolism of ","suffix":" [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"67","endOffset":"79","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"149","endOffset":"161","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"231","endOffset":"243","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ly to increase the risk of toxicity at therapeutic doses of ","suffix":". The data suggest that neither cytochrome P450 3A4 nor P-gp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"76","endOffset":"88","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[1]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[1]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[1]/span[1]","prefix":"Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of ","suffix":" on low-density lipoprotein cholesterol in patients with hyp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"108","endOffset":"120","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[2]/span[1]","prefix":"k MJ. No effect of age or gender on the pharmacokinetics of ","suffix":"—a new HMG-CoA reductase inhibitor. ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[19]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[19]/span[1]","prefix":"Hull CK, Penman AD, Smith CK, Martin PD. Quantification of ","suffix":" in human plasma by automated solid-phase extraction using t","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"65","endOffset":"77","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[21]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[21]/span[1]","prefix":"n PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No effect of ","suffix":" on the pharmacokinetics of digoxin in healthy volunteers l.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"449","endOffset":"461","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"194","endOffset":"206","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":" the first dose on day 1 until 96 h after administration of ","suffix":" in each dosing period), the consumption of caffeine-contain","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"372","endOffset":"384","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"om midnight before day 1 until 96 h after administration of ","suffix":" in each dosing period), and concomitant medications (none p","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"25","endOffset":"37","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"Blood samples (9 ml) for ","suffix":" assay were taken before administration of rosuvastatin on d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" for rosuvastatin assay were taken before administration of ","suffix":" on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"206","endOffset":"218","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"357","endOffset":"369","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"28","endOffset":"40","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"The blood samples taken for ","suffix":" assay were also used to obtain plasma for active and total ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"206","endOffset":"218","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"357","endOffset":"369","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"Lack of effect of ketoconazole on the pharmacokinetics of ","suffix":" in healthy subjects","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","prefix":"Following coadministration with ketoconazole, ","suffix":" geometric least square mean AUC(0,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"43","endOffset":"55","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"Ketoconazole did not produce any change in ","suffix":" pharmacokinetics in healthy subjects. The data suggest that","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","prefix":"CYP3A4, ketoconazole, P-glycoprotein, ","suffix":"","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"243","endOffset":"255","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"The pharmacokinetics of ","suffix":" following single- and multiple-dose administration of the d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"Elimination of ","suffix":" is primarily via the liver. In a clinical trial [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"337","endOffset":"349","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[1]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[1]/p[2]","prefix":"uring the washout period following the first dosing period (","suffix":" + placebo)]. This withdrawal was considered unlikely to hav","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"449","endOffset":"461","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"194","endOffset":"206","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":" the first dose on day 1 until 96 h after administration of ","suffix":" in each dosing period), the consumption of caffeine-contain","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"372","endOffset":"384","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"om midnight before day 1 until 96 h after administration of ","suffix":" in each dosing period), and concomitant medications (none p","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"25","endOffset":"37","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"Blood samples (9 ml) for ","suffix":" assay were taken before administration of rosuvastatin on d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" for rosuvastatin assay were taken before administration of ","suffix":" on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"28","endOffset":"40","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"The blood samples taken for ","suffix":" assay were also used to obtain plasma for active and total ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"107","endOffset":"119","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"t the 90% confidence interval (CI) for the treatment ratio (","suffix":" + ketoconazole/rosuvastatin + placebo) of the geometric lea","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"135","endOffset":"147","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"l (CI) for the treatment ratio (rosuvastatin + ketoconazole/","suffix":" + placebo) of the geometric least square means (gls","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"40","endOffset":"52","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"Geometric mean plasma concentrations of ","suffix":" over time when coadministered with ketoconazole or placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"148","endOffset":"160","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"ketoconazole or placebo. ○, Rosuvastatin + ketoconazole; ▪, ","suffix":" + placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"Summary pharmacokinetic parameters of ","suffix":", and results of the statistical analysis of the plasma AUC(","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"94","endOffset":"106","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ma concentration-time curves measured to a common point for ","suffix":" and active and total HMG-CoA reductase inhibitors indicated","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"230","endOffset":"242","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"ations of active and total HMG-CoA reductase inhibitors and ","suffix":" over time when rosuvastatin was coadministered with ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"MG-CoA reductase inhibitors and rosuvastatin over time when ","suffix":" was coadministered with ketoconazole. A similar pattern was","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"201","endOffset":"213","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"nistered with ketoconazole. A similar pattern was seen when ","suffix":" was coadministered with placebo. ○,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"20","endOffset":"32","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"Coadministration of ","suffix":" and the potent CYP3A4 inhibitor ketoconazole did not produc","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"234","endOffset":"246","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"hat ketoconazole had no effect on the systemic clearance of ","suffix":", as individual plasma concentration profiles, including the","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"In contrast to ","suffix":", atorvastatin [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"oncentrations were measured in this trial. The finding that ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"327","endOffset":"339","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"643","endOffset":"655","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" support for previous data indicating limited metabolism of ","suffix":" [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"67","endOffset":"79","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"149","endOffset":"161","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"231","endOffset":"243","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ly to increase the risk of toxicity at therapeutic doses of ","suffix":". The data suggest that neither cytochrome P450 3A4 nor P-gp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"76","endOffset":"88","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[1]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[1]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[1]/span[1]","prefix":"Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of ","suffix":" on low-density lipoprotein cholesterol in patients with hyp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"108","endOffset":"120","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[2]/span[1]","prefix":"k MJ. No effect of age or gender on the pharmacokinetics of ","suffix":"—a new HMG-CoA reductase inhibitor. ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[19]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[19]/span[1]","prefix":"Hull CK, Penman AD, Smith CK, Martin PD. Quantification of ","suffix":" in human plasma by automated solid-phase extraction using t","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"65","endOffset":"77","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[21]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[21]/span[1]","prefix":"n PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No effect of ","suffix":" on the pharmacokinetics of digoxin in healthy volunteers l.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"Lack of effect of ketoconazole on the pharmacokinetics of ","suffix":" in healthy subjects","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","prefix":"Following coadministration with ketoconazole, ","suffix":" geometric least square mean AUC(0,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"43","endOffset":"55","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"Ketoconazole did not produce any change in ","suffix":" pharmacokinetics in healthy subjects. The data suggest that","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","prefix":"CYP3A4, ketoconazole, P-glycoprotein, ","suffix":"","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"243","endOffset":"255","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"The pharmacokinetics of ","suffix":" following single- and multiple-dose administration of the d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"Elimination of ","suffix":" is primarily via the liver. In a clinical trial [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"337","endOffset":"349","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[1]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[1]/p[2]","prefix":"uring the washout period following the first dosing period (","suffix":" + placebo)]. This withdrawal was considered unlikely to hav","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"449","endOffset":"461","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"194","endOffset":"206","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":" the first dose on day 1 until 96 h after administration of ","suffix":" in each dosing period), the consumption of caffeine-contain","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"372","endOffset":"384","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"om midnight before day 1 until 96 h after administration of ","suffix":" in each dosing period), and concomitant medications (none p","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"25","endOffset":"37","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"Blood samples (9 ml) for ","suffix":" assay were taken before administration of rosuvastatin on d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" for rosuvastatin assay were taken before administration of ","suffix":" on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"28","endOffset":"40","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"The blood samples taken for ","suffix":" assay were also used to obtain plasma for active and total ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"107","endOffset":"119","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"t the 90% confidence interval (CI) for the treatment ratio (","suffix":" + ketoconazole/rosuvastatin + placebo) of the geometric lea","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"135","endOffset":"147","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":"l (CI) for the treatment ratio (rosuvastatin + ketoconazole/","suffix":" + placebo) of the geometric least square means (gls","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"40","endOffset":"52","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"Geometric mean plasma concentrations of ","suffix":" over time when coadministered with ketoconazole or placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"148","endOffset":"160","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"ketoconazole or placebo. ○, Rosuvastatin + ketoconazole; ▪, ","suffix":" + placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"Summary pharmacokinetic parameters of ","suffix":", and results of the statistical analysis of the plasma AUC(","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"94","endOffset":"106","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ma concentration-time curves measured to a common point for ","suffix":" and active and total HMG-CoA reductase inhibitors indicated","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"230","endOffset":"242","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"ations of active and total HMG-CoA reductase inhibitors and ","suffix":" over time when rosuvastatin was coadministered with ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"MG-CoA reductase inhibitors and rosuvastatin over time when ","suffix":" was coadministered with ketoconazole. A similar pattern was","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"201","endOffset":"213","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"nistered with ketoconazole. A similar pattern was seen when ","suffix":" was coadministered with placebo. ○,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"20","endOffset":"32","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"Coadministration of ","suffix":" and the potent CYP3A4 inhibitor ketoconazole did not produc","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"234","endOffset":"246","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"hat ketoconazole had no effect on the systemic clearance of ","suffix":", as individual plasma concentration profiles, including the","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"In contrast to ","suffix":", atorvastatin [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"oncentrations were measured in this trial. The finding that ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"327","endOffset":"339","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"643","endOffset":"655","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" support for previous data indicating limited metabolism of ","suffix":" [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"67","endOffset":"79","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"149","endOffset":"161","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"231","endOffset":"243","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ly to increase the risk of toxicity at therapeutic doses of ","suffix":". The data suggest that neither cytochrome P450 3A4 nor P-gp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"76","endOffset":"88","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[1]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[1]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[1]/span[1]","prefix":"Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of ","suffix":" on low-density lipoprotein cholesterol in patients with hyp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"108","endOffset":"120","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[2]/span[1]","prefix":"k MJ. No effect of age or gender on the pharmacokinetics of ","suffix":"—a new HMG-CoA reductase inhibitor. ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[19]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[19]/span[1]","prefix":"Hull CK, Penman AD, Smith CK, Martin PD. Quantification of ","suffix":" in human plasma by automated solid-phase extraction using t","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"65","endOffset":"77","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[21]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[21]/span[1]","prefix":"n PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No effect of ","suffix":" on the pharmacokinetics of digoxin in healthy volunteers l.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"643","endOffset":"655","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" support for previous data indicating limited metabolism of ","suffix":" [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"40","endOffset":"52","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"Geometric mean plasma concentrations of ","suffix":" over time when coadministered with ketoconazole or placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"","suffix":" (Crestor®) is an inhibitor of 3-hydroxy-3-methylglutaryl co","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"116","endOffset":"128","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"r time when coadministered with ketoconazole or placebo. ○, ","suffix":" + ketoconazole; ▪, rosuvastatin + placebo.","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"","suffix":" and ketoconazole were well tolerated when coadministered. T","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"45","endOffset":"57","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[18]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[18]/span[1]","prefix":"Brown CDA, Windass A, Bleasby K, Lauffart B. ","suffix":" is a high affinity substrate of hepatic organic anion trans","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","prefix":"Following coadministration with ketoconazole, ","suffix":" geometric least square mean AUC(0,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","prefix":"CYP3A4, ketoconazole, P-glycoprotein, ","suffix":"","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"243","endOffset":"255","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"449","endOffset":"461","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"148","endOffset":"160","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"ketoconazole or placebo. ○, Rosuvastatin + ketoconazole; ▪, ","suffix":" + placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"230","endOffset":"242","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"327","endOffset":"339","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"67","endOffset":"79","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"149","endOffset":"161","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"76","endOffset":"88","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[1]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[1]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[1]/span[1]","prefix":"Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of ","suffix":" on low-density lipoprotein cholesterol in patients with hyp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[19]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[19]/span[1]","prefix":"Hull CK, Penman AD, Smith CK, Martin PD. Quantification of ","suffix":" in human plasma by automated solid-phase extraction using t","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"65","endOffset":"77","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[21]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[1]/div[21]/span[1]","prefix":"n PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No effect of ","suffix":" on the pharmacokinetics of digoxin in healthy volunteers l.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"Summary pharmacokinetic parameters of ","suffix":", and results of the statistical analysis of the plasma AUC(","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"94","endOffset":"106","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ma concentration-time curves measured to a common point for ","suffix":" and active and total HMG-CoA reductase inhibitors indicated","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"230","endOffset":"242","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"ations of active and total HMG-CoA reductase inhibitors and ","suffix":" over time when rosuvastatin was coadministered with ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"MG-CoA reductase inhibitors and rosuvastatin over time when ","suffix":" was coadministered with ketoconazole. A similar pattern was","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"201","endOffset":"213","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"nistered with ketoconazole. A similar pattern was seen when ","suffix":" was coadministered with placebo. ○,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"","suffix":" and ketoconazole were well tolerated when coadministered. T","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"20","endOffset":"32","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"Coadministration of ","suffix":" and the potent CYP3A4 inhibitor ketoconazole did not produc","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"234","endOffset":"246","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"hat ketoconazole had no effect on the systemic clearance of ","suffix":", as individual plasma concentration profiles, including the","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"In contrast to ","suffix":", atorvastatin [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"oncentrations were measured in this trial. The finding that ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"327","endOffset":"339","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"643","endOffset":"655","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" support for previous data indicating limited metabolism of ","suffix":" [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"67","endOffset":"79","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"149","endOffset":"161","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"231","endOffset":"243","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ly to increase the risk of toxicity at therapeutic doses of ","suffix":". The data suggest that neither cytochrome P450 3A4 nor P-gp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"206","endOffset":"218","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"357","endOffset":"369","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"76","endOffset":"88","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[1]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"cholesterol","startOffset":"130","endOffset":"141","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in ","suffix":" biosynthesis, and is effective for the treatment of patient","exact":"cholesterol"},{"setid":"PMC1884190","drugname":"cholesterol","startOffset":"347","endOffset":"358","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"ficant dose-dependent reductions in low-density lipoprotein ","suffix":" (up to 65%) and was well-tolerated [","exact":"cholesterol"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":"48","endOffset":"60","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"Some of the other HMG-CoA reductase inhibitors (","suffix":" [","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":"29","endOffset":"41","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"In contrast to rosuvastatin, ","suffix":" [","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":"29","endOffset":"41","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"In contrast to rosuvastatin, ","suffix":" [","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":"347","endOffset":"359","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ts metabolites may be affected. For example, in the case of ","suffix":", following coadministration with itraconazole, the mean AUC","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":"530","endOffset":"542","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ased 1.6- and 1.7-fold, respectively; the mean AUC(0,72) of ","suffix":" acid and lactone was increased 3.2- and 4.1-fold, respectiv","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"itraconazole","startOffset":"393","endOffset":"405","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"n the case of atorvastatin, following coadministration with ","suffix":", the mean AUC(0,72) of the active and total inhibitors was ","exact":"itraconazole"},{"setid":"PMC1884190","drugname":"alanine","startOffset":"356","endOffset":"363","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[1]/p[1]","prefix":" haematology, or urinalysis results, or if total bilirubin, ","suffix":" aminotransferase, aspartate aminotransferase, alkaline phos","exact":"alanine"},{"setid":"PMC1884190","drugname":"caffeine","startOffset":"250","endOffset":"258","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":" of rosuvastatin in each dosing period), the consumption of ","suffix":"-containing drinks/food and smoking (none permitted from mid","exact":"caffeine"},{"setid":"PMC1884190","drugname":"heparin","startOffset":"399","endOffset":"406","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" Blood samples were collected into tubes containing lithium ","suffix":" anticoagulant and centrifuged within 30 min. Plasma was the","exact":"heparin"},{"setid":"PMC1884190","drugname":"sodium acetate","startOffset":"511","endOffset":"525","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" Plasma was then harvested from the samples, mixed 1:1 with ","suffix":" buffer 0.1 ","exact":"sodium acetate"},{"setid":"PMC1884190","drugname":"acetonitrile","startOffset":"327","endOffset":"339","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":" drug-related components were isolated from plasma by using ","suffix":" : acetone (95 : 5) to precipitate plasma proteins. The supe","exact":"acetonitrile"},{"setid":"PMC1884190","drugname":"acetone","startOffset":"342","endOffset":"349","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"omponents were isolated from plasma by using acetonitrile : ","suffix":" (95 : 5) to precipitate plasma proteins. The supernatant wa","exact":"acetone"},{"setid":"PMC1884190","drugname":"edta","startOffset":"210","endOffset":"214","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":" period. Blood samples were collected into tubes containing ","suffix":" anticoagulant and centrifuged. Plasma was then harvested fr","exact":"EDTA"}],[{"setid":"PMC1459289","drugname":"nelfinavir","startOffset":"37","endOffset":"47","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","prefix":"HIV infection, statins, pravastatin, ","suffix":", drug interactions","exact":"nelfinavir"},{"setid":"PMC1459289","drugname":"nelfinavir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"","suffix":" (NFV) is an HIV protease inhibitor (PI) that has demonstrat","exact":"Nelfinavir"},{"setid":"PMC1459289","drugname":"nelfinavir","startOffset":"174","endOffset":"184","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]/strong[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]/strong[1]","prefix":"hout (day 3; —) and with (day 16; - - -) coadminstration of ","suffix":".","exact":"nelfinavir"},{"setid":"PMC1459289","drugname":"nelfinavir","startOffset":"47","endOffset":"57","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"Pravastatin pharmacokinetics parameters in the ","suffix":" arm (","exact":"nelfinavir"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","prefix":"HIV infection, statins, ","suffix":", nelfinavir, drug interactions","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"61","endOffset":"72","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"he mechanism by which these drugs reduce plasma exposure to ","suffix":" is unknown, but this drug–drug interaction is of concern be","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"153","endOffset":"164","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" drug–drug interaction is of concern because a reduction in ","suffix":" plasma concentration may adversely affect the drug's abilit","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"494","endOffset":"505","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"n inhibitor of CYP3A4 but an inducer of other CYP isoforms. ","suffix":" metabolism is complex, utilizing both oxidative and conjuga","exact":"Pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"728","endOffset":"739","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ines the hypothesis that NFV would have a similar effect on ","suffix":" pharmacokinetics as ritonavir/saquinavir.","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"222","endOffset":"233","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":" examine the effect of efavirenz on the pharmacokinetics of ","suffix":", atorvastatin, and simvastatin and the effect of NFV on the","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"314","endOffset":"325","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"imvastatin and the effect of NFV on the pharmacokinetics of ","suffix":". The efavirenz–statin interactions were recently published ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"27","endOffset":"38","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"Subjects self-administered ","suffix":" 40 mg daily in the morning for the first 3 days and on the ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"109","endOffset":"120","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"y in the morning for the first 3 days and on the fourth day ","suffix":" was administered under observation. Blood samples were obta","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"285","endOffset":"296","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"5, 1, 2, 3, 4, 6, 8, 12, and 24 h after administration, for ","suffix":" pharmacokinetics. On days 4 through 12, subjects took NFV 1","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"447","endOffset":"458","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"On days 13 through 15, subjects continued NFV and restarted ","suffix":" with the morning dose of NFV. On day 16, pravastatin and NF","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"500","endOffset":"511","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"tarted pravastatin with the morning dose of NFV. On day 16, ","suffix":" and NFV doses were administered under observation and sampl","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"603","endOffset":"614","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" under observation and samples were collected over 24 h for ","suffix":" pharmacokinetics. Fasting serum total cholesterol, triglyce","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"12","endOffset":"23","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"Samples for ","suffix":" plasma concentrations were analyzed by Advion Biosciences I","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"29","endOffset":"40","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"The primary endpoint was the ","suffix":" AUC from 0 to 24 h before and after coadministration of NFV","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"56","endOffset":"67","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"Plots of time-specific geometric mean concentrations of ","suffix":" with and without NFV are shown in ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"32","endOffset":"43","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]/strong[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/div[1]/div[2]/span[1]/strong[1]","prefix":"Geometric mean concentration of ","suffix":" at each scheduled sample time and under the two dosing cond","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"","suffix":" pharmacokinetics parameters in the nelfinavir arm (","exact":"Pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"","suffix":" has become the preferred statin because of its lack of sign","exact":"Pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"142","endOffset":"153","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"abolism by P4503A4 and results from studies suggesting that ","suffix":" is safe and tolerable in patients taking potent antiretrovi","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"23","endOffset":"34","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"The mechanism by which ","suffix":" concentrations are reduced is not known. The metabolism of ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"94","endOffset":"105","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" concentrations are reduced is not known. The metabolism of ","suffix":" is complex. Induction of non-CYP3A4 oxidation or glucuronid","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"209","endOffset":"220","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"on or glucuronidation may result in more rapid clearance of ","suffix":". In addition, hepatic transporter OATP1B1 may participate i","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"20","endOffset":"31","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"Clinical studies of ","suffix":" for the treatment of HIV-associated dyslipidemia have shown","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"145","endOffset":"156","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" shown mixed results. For example, in a randomized trial of ","suffix":" versus fenofibrate for combined HIV-associated dyslipidemia","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"255","endOffset":"266","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"sociated dyslipidemia, only 36% of subjects receiving 40 mg ","suffix":" daily met the LDL goal (median 20% decrease) and 18% met th","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"12","endOffset":"23","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"In summary, ","suffix":" remains the statin of choice in HIV-infected persons taking","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"216","endOffset":"227","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"in and atorvastatin. The observed near 50% reduction in the ","suffix":" median AUC and a trend toward less reduction in LDL when co","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"338","endOffset":"349","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"L when coadministered with NFV suggest that higher doses of ","suffix":" may need to be prescribed to achieve optimal lipid-lowering","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"464","endOffset":"475","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ering activity. It remains unclear what the optimal dose of ","suffix":" is to achieve maximal lipid-lowering activity safely in HIV","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"669","endOffset":"680","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"hat greater improvements in lipid levels may be observed if ","suffix":" doses are adjusted in the setting of agents that are known ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"864","endOffset":"875","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"g the safety, tolerability, and efficacy of higher doses of ","suffix":" are warranted.","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"simvastatin","startOffset":"253","endOffset":"264","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"z on the pharmacokinetics of pravastatin, atorvastatin, and ","suffix":" and the effect of NFV on the pharmacokinetics of pravastati","exact":"simvastatin"},{"setid":"PMC1459289","drugname":"simvastatin","startOffset":"147","endOffset":"158","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"iretroviral therapy, given its safety profile compared with ","suffix":" and atorvastatin. The observed near 50% reduction in the pr","exact":"simvastatin"},{"setid":"PMC1459289","drugname":"ritonavir","startOffset":"347","endOffset":"356","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" PI drugs in clinical use that is not usually combined with ","suffix":", but NFV has a similar effect on the CYP enzymes as ritonav","exact":"ritonavir"},{"setid":"PMC1459289","drugname":"ritonavir","startOffset":"409","endOffset":"418","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"tonavir, but NFV has a similar effect on the CYP enzymes as ","suffix":" in that it is an inhibitor of CYP3A4 but an inducer of othe","exact":"ritonavir"},{"setid":"PMC1459289","drugname":"ritonavir","startOffset":"760","endOffset":"769","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ld have a similar effect on pravastatin pharmacokinetics as ","suffix":"/saquinavir.","exact":"ritonavir"},{"setid":"PMC1459289","drugname":"saquinavir","startOffset":"770","endOffset":"780","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"similar effect on pravastatin pharmacokinetics as ritonavir/","suffix":".","exact":"saquinavir"},{"setid":"PMC1459289","drugname":"saquinavir","startOffset":"770","endOffset":"780","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"similar effect on pravastatin pharmacokinetics as ritonavir/","suffix":".","exact":"saquinavir"},{"setid":"PMC1459289","drugname":"atorvastatin","startOffset":"235","endOffset":"247","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"effect of efavirenz on the pharmacokinetics of pravastatin, ","suffix":", and simvastatin and the effect of NFV on the pharmacokinet","exact":"atorvastatin"},{"setid":"PMC1459289","drugname":"atorvastatin","startOffset":"163","endOffset":"175","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"apy, given its safety profile compared with simvastatin and ","suffix":". The observed near 50% reduction in the pravastatin median ","exact":"atorvastatin"},{"setid":"PMC1459289","drugname":"efavirenz","startOffset":"185","endOffset":"194","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"study. The primary objectives were to examine the effect of ","suffix":" on the pharmacokinetics of pravastatin, atorvastatin, and s","exact":"efavirenz"},{"setid":"PMC1459289","drugname":"cholesterol","startOffset":"241","endOffset":"252","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"tion may adversely affect the drug's ability to lower serum ","suffix":" effectively. NFV is one of the few PI drugs in clinical use","exact":"cholesterol"},{"setid":"PMC1459289","drugname":"cholesterol","startOffset":"653","endOffset":"664","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" 24 h for pravastatin pharmacokinetics. Fasting serum total ","suffix":", triglycerides, and high density lipoprotein concentrations","exact":"cholesterol"},{"setid":"PMC1459289","drugname":"alanine","startOffset":"485","endOffset":"492","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"wo had grade 2 gastrointestinal complaints, one had grade 3 ","suffix":" aminotransferase and grade 2 aspartate aminotransferase on ","exact":"alanine"},{"setid":"PMC1459289","drugname":"fenofibrate","startOffset":"164","endOffset":"175","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"s. For example, in a randomized trial of pravastatin versus ","suffix":" for combined HIV-associated dyslipidemia, only 36% of subje","exact":"fenofibrate"}],[{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"35","endOffset":"46","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","prefix":"Subjects received rosuvastatin and ","suffix":" orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9,","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"107","endOffset":"118","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","prefix":"orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9, ","suffix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"145","endOffset":"156","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","prefix":"le dose; days 6 to 9, eltrombopag 75 mg once daily; day 10, ","suffix":" 75 mg once daily and rosuvastatin 10 mg single dose. Advers","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"21","endOffset":"32","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","prefix":"Co-administration of ","suffix":" with rosuvastatin increased geometric mean (90% confidence ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"Concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"Concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"209","endOffset":"220","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"245","endOffset":"256","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"224","endOffset":"235","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"241","endOffset":"252","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"277","endOffset":"288","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"256","endOffset":"267","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","prefix":"BCRP, drug interaction, ","suffix":", OATP1B1, rosuvastatin","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"123","endOffset":"134","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"P is important for rosuvastatin absorption and elimination. ","suffix":" inhibits OATP1B1 and BCRP ","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"Concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"Concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"209","endOffset":"220","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"245","endOffset":"256","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"224","endOffset":"235","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"241","endOffset":"252","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"277","endOffset":"288","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"256","endOffset":"267","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"","suffix":" increases plasma rosuvastatin exposure in healthy volunteer","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[1]/p[1]","prefix":"","suffix":", an oral, nonpeptide thrombopoietin receptor agonist, inhib","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"","suffix":" (GlaxoSmithKline) is an oral, nonpeptide thrombopoietin rec","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"In preclinical studies, ","suffix":" inhibited the organic anion transporting polypeptide 1B1 (O","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"148","endOffset":"159","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":" 1B1 (OATP1B1) and breast cancer resistance protein (BCRP). ","suffix":" was also identified as a BCRP substrate ","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"232","endOffset":"243","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","prefix":"itten, informed consent. Subjects received rosuvastatin and ","suffix":" orally in the following sequence: day 1, rosuvastatin 10 mg","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"338","endOffset":"349","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","prefix":"day 1, rosuvastatin 10 mg single dose; day 6 through day 9, ","suffix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"376","endOffset":"387","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","prefix":" day 6 through day 9, eltrombopag 75 mg once daily; day 10, ","suffix":" 75 mg once daily and rosuvastatin 10 mg single dose. This s","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"20","endOffset":"31","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[6]","prefix":"Steady-state plasma ","suffix":" ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"25","endOffset":"36","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[7]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[7]","prefix":"To assess the effects of ","suffix":" on rosuvastatin PK, log transformed plasma rosuvastatin AUC","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"21","endOffset":"32","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","prefix":"Co-administration of ","suffix":" with rosuvastatin increased plasma rosuvastatin AUC(0,∞) by","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"35","endOffset":"46","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","prefix":"Subjects received rosuvastatin and ","suffix":" orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9,","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"107","endOffset":"118","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","prefix":"orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9, ","suffix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"145","endOffset":"156","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","prefix":"le dose; days 6 to 9, eltrombopag 75 mg once daily; day 10, ","suffix":" 75 mg once daily and rosuvastatin 10 mg single dose. Advers","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"21","endOffset":"32","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","prefix":"Co-administration of ","suffix":" with rosuvastatin increased geometric mean (90% confidence ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"Concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"209","endOffset":"220","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"241","endOffset":"252","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","prefix":"BCRP, drug interaction, ","suffix":", OATP1B1, rosuvastatin","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"Concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"245","endOffset":"256","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"277","endOffset":"288","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"In preclinical studies, ","suffix":" inhibited the organic anion transporting polypeptide 1B1 (O","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"232","endOffset":"243","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","prefix":"itten, informed consent. Subjects received rosuvastatin and ","suffix":" orally in the following sequence: day 1, rosuvastatin 10 mg","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"338","endOffset":"349","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","prefix":"day 1, rosuvastatin 10 mg single dose; day 6 through day 9, ","suffix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"376","endOffset":"387","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","prefix":" day 6 through day 9, eltrombopag 75 mg once daily; day 10, ","suffix":" 75 mg once daily and rosuvastatin 10 mg single dose. This s","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"20","endOffset":"31","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[6]","prefix":"Steady-state plasma ","suffix":" ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"25","endOffset":"36","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[7]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[7]","prefix":"To assess the effects of ","suffix":" on rosuvastatin PK, log transformed plasma rosuvastatin AUC","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"21","endOffset":"32","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","prefix":"Co-administration of ","suffix":" with rosuvastatin increased plasma rosuvastatin AUC(0,∞) by","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"101","endOffset":"112","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[2]/div[1]/div[2]/span[1]","prefix":"time profiles. rosuvastain alone (no symbol = rosuvastain + ","suffix":") (▴); overall population (","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"57","endOffset":"68","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[4]","prefix":"For the overall population, the geometric mean of plasma ","suffix":" ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"18","endOffset":"29","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[4]/div[1]/div[2]/span[1]","prefix":"Summary of plasma ","suffix":" pharmacokinetics","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"37","endOffset":"48","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"The impact of rosuvastatin on plasma ","suffix":" PK was not formally assessed. However, eltrombopag trough c","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"88","endOffset":"99","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"n plasma eltrombopag PK was not formally assessed. However, ","suffix":" trough concentrations collected prior to co-administration ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"306","endOffset":"317","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ation of a single dose of rosuvastatin. In addition, plasma ","suffix":" exposure for the 75 mg once daily regimen (in combination w","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"454","endOffset":"465","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":" of rosuvastatin) was generally as expected based on plasma ","suffix":" exposures observed in other eltrombopag studies [","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"494","endOffset":"505","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ted based on plasma eltrombopag exposures observed in other ","suffix":" studies [","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"7","endOffset":"18","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"Plasma ","suffix":" exposures collected in the presence of rosuvastatin were si","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"218","endOffset":"229","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"tudies that have shown approximately two-fold higher plasma ","suffix":" exposures in Asian ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"45","endOffset":"56","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"In conclusion, concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"224","endOffset":"235","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"256","endOffset":"267","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"138","endOffset":"149","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[1]/div[1]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[1]/div[1]/span[1]","prefix":"s JM, Roychowdhury D, Mayer B, Stone N, Arning M. Effect of ","suffix":" on platelet counts and bleeding during treatment of chronic","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"163","endOffset":"174","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[1]/div[4]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[1]/div[4]/span[1]","prefix":"G, Luengo JI, Duffy KJ, Jenkins JM. Preclinical activity of ","suffix":" (SB-497115), an oral, nonpeptide thrombopoietin receptor ag","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"107","endOffset":"118","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[1]/div[20]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[1]/div[20]/span[1]","prefix":"V, Collins D, Erickson-Miller CL. Phase 1 clinical study of ","suffix":", an oral, nonpeptide thrombopoietin receptor agonist. ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"84","endOffset":"95","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[1]/div[22]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[1]/div[22]/span[1]","prefix":"lliams D, Wang Z, Ouellet D. Population pharmacokinetics of ","suffix":" in healthy subjects and patients with chronic idiopathic th","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"57","endOffset":"68","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[4]","prefix":"For the overall population, the geometric mean of plasma ","suffix":" ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"20","endOffset":"31","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[6]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[6]","prefix":"Steady-state plasma ","suffix":" ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"57","endOffset":"68","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[4]","prefix":"For the overall population, the geometric mean of plasma ","suffix":" ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"18","endOffset":"29","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[4]/div[1]/div[2]/span[1]","prefix":"Summary of plasma ","suffix":" pharmacokinetics","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"37","endOffset":"48","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"The impact of rosuvastatin on plasma ","suffix":" PK was not formally assessed. However, eltrombopag trough c","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"88","endOffset":"99","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"n plasma eltrombopag PK was not formally assessed. However, ","suffix":" trough concentrations collected prior to co-administration ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"306","endOffset":"317","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ation of a single dose of rosuvastatin. In addition, plasma ","suffix":" exposure for the 75 mg once daily regimen (in combination w","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"454","endOffset":"465","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":" of rosuvastatin) was generally as expected based on plasma ","suffix":" exposures observed in other eltrombopag studies [","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"494","endOffset":"505","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ted based on plasma eltrombopag exposures observed in other ","suffix":" studies [","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"7","endOffset":"18","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"Plasma ","suffix":" exposures collected in the presence of rosuvastatin were si","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"218","endOffset":"229","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"tudies that have shown approximately two-fold higher plasma ","suffix":" exposures in Asian ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"45","endOffset":"56","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"In conclusion, concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"209","endOffset":"220","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"245","endOffset":"256","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"224","endOffset":"235","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"241","endOffset":"252","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"277","endOffset":"288","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"256","endOffset":"267","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"18","endOffset":"30","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","prefix":"Subjects received ","suffix":" and eltrombopag orally: day 1, rosuvastatin 10 mg single do","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"62","endOffset":"74","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","prefix":"bjects received rosuvastatin and eltrombopag orally: day 1, ","suffix":" 10 mg single dose; days 6 to 9, eltrombopag 75 mg once dail","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"178","endOffset":"190","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[2]/p[1]","prefix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","suffix":" 10 mg single dose. Adverse event assessments were performed","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","prefix":"Co-administration of eltrombopag with ","suffix":" increased geometric mean (90% confidence interval) plasma r","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"109","endOffset":"121","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[3]/p[1]","prefix":"n increased geometric mean (90% confidence interval) plasma ","suffix":" AUC(0,∞) by 55% (42%, 69%) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[7]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[7]","prefix":"s of eltrombopag on rosuvastatin PK, log transformed plasma ","suffix":" AUC(0,∞) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[8]","prefix":"tivariate analyses of the relationship between day 1 plasma ","suffix":" AUC(0,∞) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"68","endOffset":"80","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","prefix":"istration of eltrombopag with rosuvastatin increased plasma ","suffix":" AUC(0,∞) by 55% and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"377","endOffset":"389","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[3]","prefix":"ions regarding the relationship between genotype and plasma ","suffix":" exposure. Plasma rosuvastatin AUC(0,∞) ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"407","endOffset":"419","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[3]","prefix":"p between genotype and plasma rosuvastatin exposure. Plasma ","suffix":" AUC(0,∞) ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"47","endOffset":"59","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"Concomitant administration of eltrombopag with ","suffix":" was associated with increased rosuvastatin exposure. The th","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure. The therapeutic index of HMG Co-A reductase inhib","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"105","endOffset":"117","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure. The therapeutic index of HMG Co-A reductase inhib","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/span[1]","prefix":"BCRP, drug interaction, eltrombopag, OATP1B1, ","suffix":"","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"43","endOffset":"55","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"OATP1B1 is important for hepatic uptake of ","suffix":" and BCRP is important for rosuvastatin absorption and elimi","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"82","endOffset":"94","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"or hepatic uptake of rosuvastatin and BCRP is important for ","suffix":" absorption and elimination. Eltrombopag inhibits OATP1B1 an","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"47","endOffset":"59","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"Concomitant administration of eltrombopag with ","suffix":" was associated with increased rosuvastatin exposure via inh","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure via inhibition of drug transporters. The therapeut","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"","suffix":" has known transporter-mediated drug interactions, such as i","exact":"Rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"215","endOffset":"227","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","prefix":"jects provided written, informed consent. Subjects received ","suffix":" and eltrombopag orally in the following sequence: day 1, ro","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"285","endOffset":"297","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","prefix":"in and eltrombopag orally in the following sequence: day 1, ","suffix":" 10 mg single dose; day 6 through day 9, eltrombopag 75 mg o","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"409","endOffset":"421","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[1]","prefix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","suffix":" 10 mg single dose. This study was designed and monitored in","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"438","endOffset":"450","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[1]/p[4]","prefix":"6, 8, 12, 24, 36, 48, 60, 72, 84 and 96 h after single dose ","suffix":" administration on days 1 and 10. A blood sample was obtaine","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"62","endOffset":"74","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","prefix":"asma PK samples collected on days 1 and 10 were assayed for ","suffix":" using a validated analytical method based on solid phase ex","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"330","endOffset":"342","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","prefix":"liquot of plasma, the lower limit of quantification for the ","suffix":" assay was 0.2 ng ml","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"40","endOffset":"52","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[7]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[7]","prefix":"To assess the effects of eltrombopag on ","suffix":" PK, log transformed plasma rosuvastatin AUC(0,∞) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[7]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[7]","prefix":"s of eltrombopag on rosuvastatin PK, log transformed plasma ","suffix":" AUC(0,∞) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"7","endOffset":"19","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[3]/div[1]/div[2]/span[1]","prefix":"Plasma ","suffix":" AUC(0,∞) by OATP1B1 (","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[8]","prefix":"tivariate analyses of the relationship between day 1 plasma ","suffix":" AUC(0,∞) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"18","endOffset":"30","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Summary of plasma ","suffix":" pharmacokinetics and treatment comparisons","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","prefix":"Co-administration of eltrombopag with ","suffix":" increased plasma rosuvastatin AUC(0,∞) by 55% and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"68","endOffset":"80","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","prefix":"istration of eltrombopag with rosuvastatin increased plasma ","suffix":" AUC(0,∞) by 55% and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"7","endOffset":"19","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[3]/div[1]/div[2]/span[1]","prefix":"Plasma ","suffix":" AUC(0,∞) by OATP1B1 (","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"14","endOffset":"26","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[2]/div[1]/div[2]/span[1]","prefix":"Median plasma ","suffix":" concentration–time profiles. rosuvastain alone (no symbol =","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"14","endOffset":"26","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[2]/div[1]/div[2]/span[1]","prefix":"Median plasma ","suffix":" concentration–time profiles. rosuvastain alone (no symbol =","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[3]","prefix":"bined genotype scores (approach 3) of 2–3 had higher plasma ","suffix":" exposures than subjects with scores of 0–1, and there was a","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"179","endOffset":"191","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[3]","prefix":"scores of 0–1, and there was also a trend for higher plasma ","suffix":" exposures for subjects in category 4 (approach 2). However,","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"377","endOffset":"389","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[3]","prefix":"ions regarding the relationship between genotype and plasma ","suffix":" exposure. Plasma rosuvastatin AUC(0,∞) ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"407","endOffset":"419","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[3]","prefix":"p between genotype and plasma rosuvastatin exposure. Plasma ","suffix":" AUC(0,∞) ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"7","endOffset":"19","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[3]/div[1]/div[2]/span[1]","prefix":"Plasma ","suffix":" AUC(0,∞) by OATP1B1 (","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"7","endOffset":"19","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[3]/div[1]/div[2]/span[1]","prefix":"Plasma ","suffix":" AUC(0,∞) by OATP1B1 (","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"53","endOffset":"65","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"Because it was known that Asian subjects have higher ","suffix":" exposures than non-Asian subjects [","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"55","endOffset":"67","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"The finding of statistically significant higher plasma ","suffix":" exposures in female subjects has not been reported in the l","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"14","endOffset":"26","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"The impact of ","suffix":" on plasma eltrombopag PK was not formally assessed. However","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"162","endOffset":"174","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ough concentrations collected prior to co-administration of ","suffix":" were similar to trough concentrations collected 24 h after ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"272","endOffset":"284","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":" collected 24 h after co-administration of a single dose of ","suffix":". In addition, plasma eltrombopag exposure for the 75 mg onc","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"398","endOffset":"410","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"mg once daily regimen (in combination with a single dose of ","suffix":") was generally as expected based on plasma eltrombopag expo","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"Plasma eltrombopag exposures collected in the presence of ","suffix":" were similar between Asian and non-Asian subjects. This is ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"62","endOffset":"74","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":" conclusion, concomitant administration of eltrombopag with ","suffix":" was associated with increased rosuvastatin exposure. The th","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[1]/div[4]/p[1]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure. The therapeutic index of HMG Co-A reductase inhib","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"105","endOffset":"117","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure. The therapeutic index of HMG Co-A reductase inhib","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"gemfibrozil","startOffset":"92","endOffset":"103","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"er-mediated drug interactions, such as its interaction with ","suffix":" and cyclosporin [","exact":"gemfibrozil"},{"setid":"PMC3162661","drugname":"cyclosporin","startOffset":"108","endOffset":"119","start":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[1]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":" interactions, such as its interaction with gemfibrozil and ","suffix":" [","exact":"cyclosporin"}]]}